KDM1A and neoplasm: Additionally, targeting LSD1 can enhance CD8+ T cell infiltration into tumors and boost the anti-tumor immune response through various pathways, such as increasing chemokine expression 98-100, downregulating PD-L1 33, and accumulating dsRNA 34, 95.